Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study
| العنوان: | Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study |
|---|---|
| المؤلفون: | Yosuke Okada, Yoshiya Tanaka, Kenichi Tanaka, Akemi Tokutsu |
| المصدر: | Scientific Reports, Vol 12, Iss 1, Pp 1-8 (2022) Scientific Reports |
| بيانات النشر: | Nature Portfolio, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Blood Glucose, Male, Comparative Effectiveness Research, Pediatrics, medicine.medical_specialty, Time Factors, endocrine system diseases, Recombinant Fusion Proteins, Science, Glucagon-Like Peptides, Glycemic Control, Type 2 diabetes, Incretins, Glucagon-Like Peptide-1 Receptor, Article, Endocrinology, Japan, medicine, Humans, Hypoglycemic Agents, Aged, Retrospective Studies, Glycated Hemoglobin, Multidisciplinary, business.industry, Liraglutide, Endocrine system and metabolic diseases, nutritional and metabolic diseases, Retrospective cohort study, Middle Aged, medicine.disease, Immunoglobulin Fc Fragments, Treatment Outcome, Diabetes Mellitus, Type 2, Medicine, Female, Dulaglutide, business, Biomarkers, medicine.drug |
| الوصف: | Real-world data comparing the effectiveness of various glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in type 2 diabetes mellitus (T2DM) are limited. We investigated the clinical effectiveness of liraglutide and dulaglutide in Japanese T2DM in a real-world setting. This retrospective study included 179 patients with T2DM who were treated with GLP-1 RA for at least 12 months (liraglutide, n = 97; dulaglutide, n = 82). We used stabilized propensity score-based inverse probability of treatment weighting (IPTW) to reduce selection bias and confounding by observed covariates. Changes in glycated hemoglobin (HbA1c) at the end of the 12-month treatment were evaluated. After adjustment by stabilized propensity score-based IPTW, no significant differences were observed in patient characteristics between the liraglutide and dulaglutide groups. HbA1c was significantly lower at 12 months in both groups (liraglutide, 8.9 to 7.4%; dulaglutide, 8.7 to 7.5%). Multivariate linear regression analysis showed no differences in the extent of changes in HbA1c at 12 months between the two agents. High baseline HbA1c, the addition of GLP-1 RA treatment modality, and in-hospital initiation of GLP-1 RA treatment were identified as significant contributing factors to HbA1c reduction. The effects of liraglutide and dulaglutide on lowering HbA1c levels at 12 months were comparable in a real-world setting. |
| اللغة: | English |
| تدمد: | 2045-2322 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::220ad8c648309d60a7c8343e2785c16bTest https://doaj.org/article/2449d6ce59ed48908348abe55a6049dfTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....220ad8c648309d60a7c8343e2785c16b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20452322 |
|---|